Data Insights

Mecbotamab vedotin by BioAtla for Cervical Cancer: Likelihood of Approval

Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mecbotamab Vedotin in Cervical Cancer

Data Insights

Evalstotug by BioAtla for Uveal Melanoma: Likelihood of Approval

Evalstotug is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Evalstotug in Uveal Melanoma

Data Insights

Evalstotug by BioAtla for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Evalstotug is under clinical development by BioAtla and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Evalstotug in Gastroesophageal (GE) Junction Carcinomas

Data Insights

BA-3182 by BioAtla for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Triple-Negative Breast Cancer (TNBC)

Data Insights

BA-3182 by BioAtla for Adenocarcinoma: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Adenocarcinoma

Data Insights

BA-3182 by BioAtla for Non-Small Cell Lung Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Non-Small Cell Lung Cancer

Data Insights

BA-3182 by BioAtla for Small-Cell Lung Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Small-Cell Lung Cancer

Data Insights

BA-3182 by BioAtla for Pancreatic Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Pancreatic Cancer

Data Insights

BA-3182 by BioAtla for Colon Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Colon Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Colon Cancer

Data Insights

BA-3182 by BioAtla for Colorectal Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Colorectal Cancer

Data Insights

BA-3182 by BioAtla for Prostate Cancer: Likelihood of Approval

BA-3182 is under clinical development by BioAtla and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BA-3182 in Prostate Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Soft Tissue Sarcoma: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Soft Tissue Sarcoma

Data Insights

Mecbotamab vedotin by BioAtla for Pancreatic Cancer: Likelihood of Approval

Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mecbotamab Vedotin in Pancreatic Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Evalstotug by BioAtla for Solid Tumor: Likelihood of Approval

Evalstotug is under clinical development by BioAtla and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Data Insights

Evalstotug by BioAtla for Melanoma: Likelihood of Approval

Evalstotug is under clinical development by BioAtla and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...

Data Insights

Risk adjusted net present value: What is the current valuation of BioAtla's Ozuriftamab vedotin?

Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Oropharyngeal Cancer. According...

Net Present Value Model: BioAtla Inc's Ozuriftamab vedotin

Data Insights

Risk adjusted net present value: What is the current valuation of BioAtla's Mecbotamab vedotin?

Mecbotamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Cervical Cancer. According...

Net Present Value Model: BioAtla Inc's Mecbotamab vedotin

Data Insights

BA-3071 by BioAtla for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

BA-3071 is under clinical development by BioAtla and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Data Insights

BA-3071 by BioAtla for Uveal Melanoma: Likelihood of Approval

BA-3071 is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...